• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本胃肠胰神经内分泌肿瘤的流行病学研究。

Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan.

机构信息

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

出版信息

J Gastroenterol. 2010 Feb;45(2):234-43. doi: 10.1007/s00535-009-0194-8.

DOI:10.1007/s00535-009-0194-8
PMID:20058030
Abstract

BACKGROUND

There have been few epidemiological studies on gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Japan.

METHODS

We examined the epidemiology of GEP-NETs [pancreatic endocrine tumors (PETs) and gastrointestinal neuroendocrine tumors (GI-NETs)] in Japan in 2005 using a nationwide stratified random sampling method.

RESULTS

A total of 2,845 individuals received treatment for PETs. Prevalence was estimated as 2.23/100,000 with an annual onset incidence of 1.01/100,000. Non-functioning tumor (NF)-PET constituted 47.4%, followed by insulinoma (38.2%) and gastrinoma (7.9%). Distant metastases were reported in 21% patients with NF-PETs and occurred more frequently as tumor size increased (>2 cm). Multiple endocrine neoplasia type 1 (MEN-1) was detected in 10% of PETs but only in 6.1% of NF-PETs. NF-PETs were detected incidentally by physical examination in 24% patients. In 2005, an estimated 4,406 patients received treatment for GI-NETs. Prevalence was estimated as 3.45/100,000, with an annual onset incidence of 2.10/100,000. The locations of GI-NETs varied: foregut, 30.4%; midgut, 9.6%; and hindgut, 60.0%. Distant metastases were observed in 6%. Lymph node metastases occurred more frequently as tumor size increased (>1 cm). The frequency of MEN-1 complications was 1%. Physical examination revealed GI-NETs in 44% patients. The frequency of symptomatic GI-NETs was 3.4%. Interestingly, 77.1% of patients with foregut GI-NETs had type A gastritis.

CONCLUSION

Our results show there are large differences in GEP-NETs between Japan and Western nations, primarily due to differences in the presence of MEN-1 in NF-PETs and the location, symptomatic status, and prevalence of malignancy in GI-NETs.

摘要

背景

日本针对胃肠胰神经内分泌肿瘤(GEP-NETs)的流行病学研究较少。

方法

我们采用全国分层随机抽样方法,于 2005 年对日本的 GEP-NETs(胰腺内分泌肿瘤[PETs]和胃肠道神经内分泌肿瘤[GI-NETs])的流行病学进行了研究。

结果

共有 2845 人因 PETs 接受了治疗。患病率估计为 2.23/100000,年发病发病率为 1.01/100000。无功能性肿瘤(NF)-PET 占 47.4%,其次是胰岛素瘤(38.2%)和胃泌素瘤(7.9%)。21%的 NF-PET 患者出现远处转移,且随着肿瘤大小的增加(>2 cm),转移更为常见。多发性内分泌肿瘤 1 型(MEN-1)在 10%的 PETs 中检出,但仅在 6.1%的 NF-PETs 中检出。NF-PET 中有 24%的患者是通过体检偶然发现的。2005 年,估计有 4406 人因 GI-NETs 接受了治疗。患病率估计为 3.45/100000,年发病发病率为 2.10/100000。GI-NETs 的位置各不相同:前肠,30.4%;中肠,9.6%;后肠,60.0%。有 6%的患者出现远处转移。随着肿瘤大小的增加(>1 cm),淋巴结转移更为常见。MEN-1 并发症的发生率为 1%。体检发现 44%的 GI-NETs 患者存在 GI-NETs。有症状的 GI-NETs 的发生率为 3.4%。有趣的是,77.1%的前肠 GI-NETs 患者患有 A 型胃炎。

结论

我们的研究结果表明,日本和西方国家的 GEP-NETs 存在很大差异,主要是由于 NF-PETs 中 MEN-1 的存在以及 GI-NETs 的位置、症状状态和恶性肿瘤的发生率不同所致。

相似文献

1
Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan.日本胃肠胰神经内分泌肿瘤的流行病学研究。
J Gastroenterol. 2010 Feb;45(2):234-43. doi: 10.1007/s00535-009-0194-8.
2
Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis.日本胰腺和胃肠神经内分泌肿瘤的流行病学趋势:一项全国性调查分析
J Gastroenterol. 2015 Jan;50(1):58-64. doi: 10.1007/s00535-014-0934-2. Epub 2014 Feb 6.
3
[Results of a nationwide survey of gastrointestinal tumors in Japan].[日本全国胃肠道肿瘤调查结果]
Nihon Geka Gakkai Zasshi. 2008 May;109(3):128-32.
4
Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors.日本全国神经内分泌胃肠道肿瘤调查的初步结果。
J Gastroenterol. 2007 Jun;42(6):497-500. doi: 10.1007/s00535-007-2056-6. Epub 2007 Jun 29.
5
The prevalence and relevance of adrenal masses in patients with sporadic gastroenteropancreatic neuroendocrine tumours (GEP-NET).散发性胃肠胰神经内分泌肿瘤(GEP-NET)患者肾上腺肿块的患病率及相关性。
Clin Endocrinol (Oxf). 2013 Jun;78(6):950-6. doi: 10.1111/cen.12046. Epub 2013 Apr 1.
6
Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.日本胃-肠-胰神经内分泌肿瘤(GEP-NEN)患者的最新流行病学:一项基于人群的研究。
BMC Cancer. 2020 Nov 14;20(1):1104. doi: 10.1186/s12885-020-07581-y.
7
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.美国神经内分泌肿瘤患者的发病率、患病率和生存结局趋势。
JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589.
8
Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life.在生命的第二个十年中,多发性内分泌腺瘤病 1 型中功能性和非功能性胰腺神经内分泌肿瘤的外显率。
J Clin Endocrinol Metab. 2014 Jan;99(1):E89-96. doi: 10.1210/jc.2013-1768. Epub 2013 Dec 20.
9
Natural history and outcome in Chinese patients with gastroenteropancreatic neuroendocrine tumours: - a 17-year retrospective analysis.中国胃肠胰神经内分泌肿瘤患者的自然病史及预后:一项17年的回顾性分析。
BMC Endocr Disord. 2016 Feb 24;16:12. doi: 10.1186/s12902-016-0087-9.
10
The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.胃胰肠神经内分泌肿瘤的多样性和共性。
Langenbecks Arch Surg. 2011 Mar;396(3):273-98. doi: 10.1007/s00423-011-0739-1. Epub 2011 Jan 28.

引用本文的文献

1
The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapy.PANEN列线图:为接受肽受体放射性核素治疗的转移性胰腺神经内分泌肿瘤患者提供临床决策支持。
Front Endocrinol (Lausanne). 2025 Jun 24;16:1514792. doi: 10.3389/fendo.2025.1514792. eCollection 2025.
2
Pancreatic Neuroendocrine Tumor Leading to a Diagnosis of Multiple Endocrine Neoplasia Type 1.导致1型多发性内分泌腺瘤病诊断的胰腺神经内分泌肿瘤
DEN Open. 2025 Jun 6;6(1):e70160. doi: 10.1002/deo2.70160. eCollection 2026 Apr.
3
A Case of Pancreatic Metastasis of Renal Cancer Coexisting With a Pancreatic Neuroendocrine Tumor in a Patient Diagnosed With Fulminant Type 1 Diabetes Mellitus.

本文引用的文献

1
Neuroendocrine tumors: novel approaches in the age of targeted therapy.神经内分泌肿瘤:靶向治疗时代的新方法
Oncology (Williston Park). 2008 Dec;22(14):1617-23; discussion 1623-4, 1629.
2
Proposed staging system for colon carcinoid tumors based on an analysis of 2,459 patients.基于对2459例患者的分析提出的结肠类癌肿瘤分期系统。
J Am Coll Surg. 2008 Dec;207(6):874-81. doi: 10.1016/j.jamcollsurg.2008.08.013.
3
Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.胃肠道神经内分泌肿瘤:胰腺内分泌肿瘤
一名暴发性1型糖尿病患者同时存在肾癌胰腺转移与胰腺神经内分泌肿瘤的病例
Cureus. 2025 Feb 23;17(2):e79489. doi: 10.7759/cureus.79489. eCollection 2025 Feb.
4
Endoscopic resection of rectal neuroendocrine tumors: zero disease-related deaths during a 10-year follow-up period.直肠神经内分泌肿瘤的内镜切除:10年随访期内无疾病相关死亡病例。
BMC Gastroenterol. 2025 Mar 11;25(1):155. doi: 10.1186/s12876-025-03736-y.
5
Recurrence pattern and mapping of lymph node metastases from rectal neuroendocrine tumors.直肠神经内分泌肿瘤的复发模式及淋巴结转移的定位
Int J Colorectal Dis. 2025 Feb 25;40(1):52. doi: 10.1007/s00384-025-04820-1.
6
Role of endoscopic ultrasound in the diagnosis and local ablative therapy of pancreatic neuroendocrine tumors.内镜超声在胰腺神经内分泌肿瘤诊断及局部消融治疗中的作用
Korean J Intern Med. 2025 Mar;40(2):170-180. doi: 10.3904/kjim.2024.293. Epub 2025 Feb 25.
7
-induced promotes the malignant progression of pancreatic neuroendocrine neoplasms through -mediated lipid metabolism.-诱导通过-介导的脂质代谢促进胰腺神经内分泌肿瘤的恶性进展。
Int J Biol Sci. 2025 Jan 27;21(4):1478-1496. doi: 10.7150/ijbs.103428. eCollection 2025.
8
Efficacy and safety of endoscopic ultrasonography-guided radiofrequency ablation of small pancreatic neuroendocrine neoplasms: A prospective, pilot study.内镜超声引导下射频消融治疗小胰腺神经内分泌肿瘤的疗效与安全性:一项前瞻性试点研究。
DEN Open. 2025 Jan 29;5(1):e70073. doi: 10.1002/deo2.70073. eCollection 2025 Apr.
9
NON-FUNCTIONING SPORADIC PANCREATIC NEUROENDOCRINE TUMOR IS AN INDEPENDENT RISK FACTOR FOR RECURRENCE AFTER SURGICAL TREATMENT.无功能散发性胰腺神经内分泌肿瘤是手术治疗后复发的独立危险因素。
Arq Bras Cir Dig. 2025 Jan 20;37:e1857. doi: 10.1590/0102-6720202400063e1857. eCollection 2025.
10
Efficacy and safety of endoscopic ultrasonography-guided ethanol injections of small pancreatic neuroendocrine neoplasms: a prospective multicenter study.内镜超声引导下乙醇注射治疗小胰腺神经内分泌肿瘤的疗效与安全性:一项前瞻性多中心研究。
Endoscopy. 2025 Apr;57(4):321-329. doi: 10.1055/a-2452-4607. Epub 2024 Oct 25.
Gastroenterology. 2008 Nov;135(5):1469-92. doi: 10.1053/j.gastro.2008.05.047. Epub 2008 Aug 12.
4
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.胃肠胰神经内分泌肿瘤长期预后的预测因素
Endocr Relat Cancer. 2008 Dec;15(4):1083-97. doi: 10.1677/ERC-08-0017. Epub 2008 Jul 4.
5
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.“类癌”百年之后:美国35825例神经内分泌肿瘤的流行病学及预后因素
J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377.
6
Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.一种新型TNM分类系统对上消化道胰腺神经内分泌肿瘤的预后相关性
Cancer. 2008 Jul 15;113(2):256-65. doi: 10.1002/cncr.23549.
7
Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study.与神经内分泌肿瘤相关的风险因素:一项基于美国的病例对照研究。
Int J Cancer. 2008 Aug 15;123(4):867-73. doi: 10.1002/ijc.23529.
8
Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours.180例无功能性胰腺内分泌肿瘤单中心系列研究中诊断时的预后因素及世界卫生组织分类的价值
Ann Oncol. 2008 May;19(5):903-8. doi: 10.1093/annonc/mdm552. Epub 2008 Jan 21.
9
Gastroenteropancreatic neuroendocrine tumours.胃肠胰神经内分泌肿瘤
Lancet Oncol. 2008 Jan;9(1):61-72. doi: 10.1016/S1470-2045(07)70410-2.
10
Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors.日本全国神经内分泌胃肠道肿瘤调查的初步结果。
J Gastroenterol. 2007 Jun;42(6):497-500. doi: 10.1007/s00535-007-2056-6. Epub 2007 Jun 29.